Floatz logo

Sirolimus

Long COVID-19

Icahn School of Medicine at Mount SinaiSmall moleculePhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

31 Active assets in the Long COVID-19 cohort.

Asset / SponsorPhaseRating
Immulina Tm
University of Mississippi Medical Center
Phase 3BB
Melatonin
Duke University
Phase 2B
NORVIR
Kanecia Obie Zimmerman
Phase 2B
Ivabradine
Kanecia Obie Zimmerman
Phase 2B
Paxlovid
Kanecia Obie Zimmerman
Phase 2B

View all 31 →

Same molecule, other indications

Sirolimus is also rated in:

tuberous sclerosisActive
BBB
Indicative · Phase 3
73 / 100
View asset →
disease related to transplantationDormant
BBB
Indicative · Phase 4
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmActive
BB
Indicative · Phase 2
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →